Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 42, 2010, Pages 17939-17944

  Kolishetti, Nagesh ^a,b   Dhar, Shanta ^b   Valencia, Pedro M ^c   Lin, Lucy Q ^c   Karnik, Rohit ^c   Lippard, Stephen J ^b   Langer, Robert ^b   Farokhzad, Omid C ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Chemotherapy; Drug delivery; Polymer drug conjugate; Targeting; Temporal release

Indexed keywords

CELL NUCLEUS DNA; CISPLATIN; COPOLYMER; DOCETAXEL; HYDROXYL GROUP; MACROGOL; NANOPARTICLE; PEPTIDE APTAMER; PLATINUM; POLYGLACTIN; POLYLACTIDE; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ARTICLE; CANCER CELL; CYTOTOXICITY; DNA CROSS LINKING; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; ELECTROCHEMISTRY; ENCAPSULATION; ENDOCYTOSIS; HUMAN; HUMAN CELL; IC 50; MICROFLUIDICS; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG THERAPY, COMBINATION; ELECTROCHEMISTRY; ENDOCYTOSIS; HUMANS; MALE; NANOPARTICLES; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 78149260773     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1011368107     Document Type: Article

References (46)

1. Welch DR (1987) Biologic considerations for drug targeting in cancer patients. Cancer Treat Rev 14:351-358.
2. Strebhardt K, Ullrich A (2008) Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer 8:473-480. (Pubitemid 351752547)
3. Jia J, et al. (2009) Mechanisms of drug combinations: Interaction and network perspectives. Nat Rev Drug Discovery 8:111-128.
4. Orjuela P, Gonzalez I, Osorio L (2004) Combination therapy as a strategy to prevent antimalarial drug resistance. Biomedica 24:423-437.
5. de Gaetano Donati K, Rabagliati R, Iacoviello L, Cauda R (2004) HIV infection, HAART, and endothelial adhesion molecules: Current perspectives. Lancet Infect Dis 4:213-222.
6. Suarez-Pinzon WL, et al. (2008) Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57:3281-3288.
7. Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Delivery Rev 54:631-651.
8. LaVan DA, McGuire T, Langer R (2003) Small-scale systems for in vivo drug delivery. Nat Biotechnol 21:1184-1191. (Pubitemid 37186175)
9. Brannon-Peppas L, Blanchette JO (2004) Nanoparticle and targeted systems for cancer therapy. Adv Drug Delivery Rev 56:1649-1659. (Pubitemid 39177694)
10. Langer R (1998) Drug delivery and targeting. Nature 392(Suppl 6679):5-10.
11. Langer R (2001) Drug delivery: Drugs on target. Science 293(5527):58-59.
12. Zhang L, et al. (2008) Nanoparticles in medicine: Therapeutic applications and developments. Clin Pharmacol Ther 83:761-769. (Pubitemid 351556021)
13. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ (2008) Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 105:17356-17361.
14. Farokhzad OC, et al. (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103:6315-6320.
15. Farokhzad OC, et al. (2004) Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res 64:7668-7672. (Pubitemid 39446893)
16. Gu F, et al. (2008) Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 105:2586-2591.
17. Lupold SE, Hicke BJ, Lin Y, Coffey DS (2002) Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 62:4029-4033.
18. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH (1998) Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 83:2259-2269.
19. Chang SS, et al. (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59:3192-3198.
20. Ghosh A, Heston WDW (2004) Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 91:528-539.
21. Morris MJ, et al. (2007) Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res 13:2707-2713.
22. Milowsky MI, et al. (2007) Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 25:540-547.
23. Wright GL, Jr, et al. (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326-334. (Pubitemid 26279634)
24. Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharmaceut 5:505-515.
25. Cheng J, et al. (2007) Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28:869-876. (Pubitemid 44667020)
26. Chen H, et al. (2009) Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment. Angew Chem, Int Ed 48:9295-9299.
27. Adelstein DJ, et al. (2010) Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A southwest oncology group phase II trial (S0216). Head Neck-J Sci Spec 32:221-228.
28. Jamieson ER, Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99:2467-2498.
29. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573-584.
30. Tankanow RM (1998) Docetaxel: A taxoid for the treatment of metastatic breast cancer. Am J Health-Syst Ph 55:1777-1791.
31. Kumar A, Wakelee H (2006) Second- and third-line treatments in non-small cell lung cancer. Curr Treat Option Oncol 7:37-49.
32. Thuss-Patience PC, Kretzschmar A, Reichardt P (2006) Docetaxel in the treatment of gastric cancer. Future Oncol 2:603-620.
33. Markman M (2007) New, expanded, and modified use of approved antineoplastic agents in ovarian cancer. Oncologist 12:186-190.
34. Khuri FR (2002) Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy. Oncology 16(Suppl 6):53-62.
35. Ajani JA, et al. (2007) Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 study group. J Clin Oncol 25:3210-3216.
36. Leemhuis M, et al. (2006) Functionalized poly(α-hydroxy acid)s via ring-opening polymerization: Toward hydrophilic polyesters with pendant hydroxyl groups. Macromolecules 39:3500-3508. (Pubitemid 43798226)
37. Gerhardt WW, et al. (2006) Functional lactide monomers: Methodology and polymerization. Biomacromolecules 7:1735-1742.
38. Karnik R, et al. (2008) Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett 8:2906-2912.
39. Buxton DB (2009) Nanomedicine for the management of lung and blood diseases. Nanomedicine 4:331-339.
40. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE (2008) Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharmaceut 5:487-495.
41. Avgoustakis K, et al. (2002) PLGA-mPEG nanoparticles of cisplatin: In vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Controlled Release 79:123-135.
42. Bell DN, et al. (2008) Comparitive protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro. Clin Exp Pharmacol Physiol 35:1440-1446.
43. Choi S, et al. (1998) Reduction and anticancer activity of platinum(IV) complexes. Inorg Chem 37:2500-2504. (Pubitemid 128487903)
44. Budman DR, Calabro A, Kreis W (2002) Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 13:1011-1016. (Pubitemid 36020671)
45. Dhar S, Daniel WL, Giljohann DA, Mirkin CA, Lippard SJ (2009) Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads. J Am Chem Soc 131:14652-14653.
46. Noga DE, et al. (2008) Synthesis and modification of functional poly(lactide) copolymers: Toward biofunctional materials. Biomacromolecules 9:2056-2062.